Navigation Links
Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury
Date:11/18/2010

nts for ARDS.  Because infection is often the underlying cause of ARDS, appropriate antibiotic therapy is administered. There are approximately 150,000 cases of ARDS in the United States annually and the mortality rate is approximately 50%. Patients who survive ARDS will typically experience ongoing mild to moderate impairment of lung function, with poorer health-related quality of life after hospitalization compared to patients who were hospitalized without ARDS.  

About ALS-886

ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in both scavenging existing free radicals and sequestering free iron. The goal of treatment with ALS-886 for ARDS will be to reduce the tissue damage brought about by the free radicals in the lungs. Previous animal toxicology studies have demonstrated the safety and benign side effect profile of ALS-886. This could prove beneficial in the use of the compound in the critical care setting. In addition, the mild safety profile shown in animal studies supports the possibility that ALS-886 could be used as a prophylactic. That is, it could be administered to individuals who are at high risk of developing ARDS, such as patients suffering from sepsis or severe trauma, in order to prevent the underlying condition from leading to ARDS. ALS-886 may also have applicability for other conditions in which free radicals cause tissue damage, such as ischemic stroke and myocardial infarction. An open IND is in place to start Phase I clinical trials.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza™, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... SPEX ) announced today that it has signed letters ... pharmaceutical ingredients,to supply a portion of the D-tagatose used ... sugar as a treatment for Type 2 diabetes. Inalco ... D- tagatose for the Spherix New Drug Application (NDA) ...
... today announced that it submitted a supplemental New ... Administration (FDA) for approval of a new,indication for ... of patients with Chronic Obstructive,Pulmonary Disease (COPD). SYMBICORT ... asthma in patients 12 years and older., ...
Cached Medicine Technology:Spherix D-tagatose to be Supplied by Inalco SpA 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 4AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 5
(Date:8/29/2015)... ... 2015 , ... Vascular Health Sciences announced today that an ... HP, and that all claims and counterclaims have been irrevocably dismissed. , In ... the United States District Court for the Southern District of Texas for breach ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers how this software allows businesses to track product movement from beginning to end. ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Haryana government claimed Monday that there was a minor improvement in ... the lowest figure in the country., ,Latest reports suggested that ... now at 822 females per thousand males, director general of health ... had recorded an abysmally low ratio of 819, which placed it ...
... had published a research report on recommendations to ... health-worker performance is a widespread problem for // ... of The Lancet researchers had reviewed the existing ... performance can be achieved., ,Millions of children ...
... Science is usually viewed with awe, not to mention a little ... people cannot understand, let alone hope to enter. Such an // ... the use of science., ,If the public is to have ... it should fist have a clear sense of what science can ...
... second largest number of HIV/AIDS afflicted people in the world ... of India are very real according to a World Economic ... businesses expect an effect on the business due to AIDS ... surveyed recently and 46 per cent report some ...
... The Office of Fair Trading is responsible for checking ... //manufacturers sell to the NHS. They have to monitor ... the prices should be reasonable. ,The Pharmaceutical ... monitors and legislates the agreement of the pricing and ...
... a disaster-planning guide to help the people who live ... hurricanes, tidal waves and cyclones. ,No matter where ... some sort of natural disaster such as a blizzard, ... are also possible. Both natural disasters and terrorist attacks ...
Cached Medicine News:Health News:Scientists Awarded Appropriately For Contribution Towards Medical Research 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2
... Test, v1.5, an FDA-approved HIV-1 RNA assay, is ... used in the regulatory approval for HIV-1 therapies, ... 10 clinical laboratories worldwide. , The ... vitro nucleic acid amplification test for the quantification ...
... ADVANCE Rapid HIV-1/2 Antibody ... qualitative immunoassay to detect ... Virus Type 1 (HIV-1) ... in oral fluid, fingerstick ...
... CHS System takes the time proven technology ... ,The VHS® Supracondylar Cable Plate is designed ... femur fractures including periprosthetic fractures. The combination ... angle of the barrel and the plate ...
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: